alexa Efficacy Of Apremilast Sustained Through Week 52 In Patients With Moderate To Severe Psoriasis Who Continued On Apremilast Or Switched From Etanercept Treatment: Results From The LIBERATE Study
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

10th Asia-Pacific Dermatology Conference
November 28-29, 2016 Melbourne, Australia

Kristian Reich, Kim A Papp, Peter van de Kerkhof, Zuoshun Zhang, Kristine Nograles and Jennifer Soung
SCIderm GmbH, Germany
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554.C1.048
Abstract
LIBERATE, a phase 3b trial, evaluated the efficacy and safety of Apremilast (APR) or Etanercept (ETN) vs. placebo (PBO) in biologic-naive patients (pts) with moderate to severe plaque psoriasis. Efficacy through Wk52 is reported. Pts (n=250) were randomized 1:1:1 to PBO, APR 30 mg BID or ETN 50 mg QW through Wk16; thereafter, all pts were switched to or continued on APR through Wk104. PASI-75 (primary endpoint, Wk16), mean percent change from baseline (MPCBL) in PASI score and safety were assessed at Wk16 and Wk52. At Wk16, PASI-75 response was achieved by significantly more pts receiving APR (39.8%) and ETN (48.2%) vs. PBO (11.9%; P<0.0001, both; APR vs. ETN, P=0.2565); the MPCBL in PASI score was −38.0% (PBO), −61.0% (APR) and −69.1% (ETN). At Wk52, PASI-75 was achieved by 46.4% (PBO/APR), 50.6% (APR/APR) and 55.4% (ETN/APR) of pts; the MPCBL in PASI score was −71.1% (PBO/APR), −73.0% (APR/APR) and −75.4% (ETN/ APR). Diarrhea, nausea and headache, AEs occurring in ≥5% of pts were mild to moderate in severity throughout the study. The exposure-adjusted incidence rates/100 pt-years for serious AEs and discontinuation rates due to AEs did not increase compared to the first 16 Wks. Weight loss >5% was experienced by 18.6%, 10.0% and 8.0% of pts in the PBO/APR, APR/APR and ETN/APR groups, respectively. In the first 16 Wks, APR was well tolerated and efficacious compared to PBO. The safety and efficacy of APR was sustained through Wk52 and maintained in pts treated with ETN who switched to APR.
Biography

Kristian Reich is a Professor of Dermatology at the Georg-August-Universitat Göttingen and leads the inflammation center at the Dermatologikum Hamburg, an international center of excellence for dermatology, plastic and vascular surgery, dermatopathology, microbiology and molecular biology. He is founding Partner and Medical Director at SCIderm, a CRO and research institute dedicated to the development of new therapies in dermatology. He is a Member of the Psoriasis Guideline Group of the German Society of Dermatology, chairs the Scientific Advisory Committee of the German Psoriasis Registry and is Board Member of the Alfred-Marchionini Foundation, the Foundation Dermatologikum and the ProDerma Foundation.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords